Excited to speak to my PharmD colleagues at HOPARX 2025! Should we really be bending clinical trial schemas in myeloma to optimize outcomes for our patients? ... Yes. Join James Davis, PharmD, BCOP #brookepeters and me on Fri 4/11 morning as we discuss why! #MMsm #downwithdex

Check out are latest episode, with a star-studded cast! 🤩 "Dex and the Cytokine City: Managing CRS with Bispecifics" #leusm #lymsm #myeloma #TwitteRx @berninini James Davis, PharmD, BCOP Victoria Nachar Anthony Perissinotti Justine Preedit creators.spotify.com/pod/show/wolve…

Check out the latest WolverHeme episode featuring delicious 🍻 and a lively discussion with a great crew of folks! ps... Victoria Nachar and I talk about our new paper #mmsm 🤓

Teclistamab for Heavily Pretreated RRMM and Renal Impairment. No difference in toxicity, ORR or survival compared to patients with normal renal function #mmsm #bmtsm Danai Dima Aimaz Afrough ashpublications.org/bloodadvances/…

And James Davis, PharmD, BCOP and I were the first in line - come join us for a great #MMsm talk about optimizing myeloma therapies as pharmacists and physicians! Cc HOPARX

Great program- thank you to our moderator Sara Scott, PharmD, BCOP , #PTCE and #HOPA James Davis, PharmD, BCOP

Final dinner at #HOPA2025 with some of my favorite folks Zahra M, PharmD, MBA, BCOP, FHOPA Victoria Nachar Taylor Weis Cory Perry, PharmD Jordan Snyder Sara Leidy, PharmD, BCOP #bringitonbacktoburgerville

Outcomes of older patients (>/= 75) with RRMM treated with teclistamab. No significant difference in CRS, ICANS or ORR #mmsm #bmtsm #Osvolsky Blood Cancer Journal nature.com/articles/s4140…

Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826 | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Great Blood Cancer Journal RW data from US #MMsm consortium, led by Danai Dima Leyla Shune MD et al! BCMA bsAbs can work in BCMA-exposed. While we await better predictive tools, time & type of prior therapy matters: - ⬆️ PFS if > 9 months since prior BCMA - ⬇️ PFS if prior BCMA was bsAb

#Myeloma Paper of the Day: US Myeloma Immunotx Consortium teclistamab data: 54% CRS (1.4% G≥3), 11% ICANS (2.2% G≥3), 42% infxns, 53% ≥PR, 45% ≥VGPR, PFS 5.8 mos, 12-mo OS 61%; BCMA CAR w/in 9 mos, hi dz/ferritin, lymphopenia reduce benefit: pubmed.ncbi.nlm.nih.gov/40629516/. #mmsm

Want to know why those other countries have lower brand drugs prices than us ? They don't have PBMs. We are the ONLY country that uses PBMs. Insane

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma | Blood Cancer Journal nature.com/articles/s4140…

#Myeloma Paper of the Day: Targeting w/ talquetamab as bridge to BCMA CAR-T shows no grade ≥3 CRS, 2% grade 3 ICANS & grade 1-2 talq unique toxicities, 71% ORR, post CAR-T 88% responded/54% CR, 2 grade ≥3 CRS, 1 grade 3 ICANS, 5% grade ≥3 infxns: pubmed.ncbi.nlm.nih.gov/40749169/. #mmsm

1/ As Luciano J Costa has said so eloquently: "The only place where BCMA must come before GPRC5D is the dictionary." Talquetamab bridging before BCMA CAR-T in myeloma - short, very effective, and rapidly becoming my preferred approach for patients with aggressive #MMsm biology!

CAR T-cell therapy for the beast that is plasma cell leukemia #PCL. 👏 led by Doug Sborov and team at Huntsman Cancer Institute doi.org/10.1182/blooda…

Excited to share our newesr manuscript! Great collab w/ US Myeloma Immunotherapy Consortium showing impact of Flu LD exposure on CAR-T outcomes! Need prospective studies to validate model but even more 👀 on personalized chemo dosing! astctjournal.org/article/S2666-…

1/ Thanks Larry (and all co-authors) and AmericanJournalofHematology for this! RW data for a frequent q in my own #MMsm clinic, namely patients starting teclistamab disappointed by D30 results after hearing "Median time to 1st response 1.1 mo"... Can we predict delayed response conversion?

How well do bsAbs work for patients with DLBCL who relapse after CAR T? depends on time to relapse post-CAR... ORR similar, however CR and OS were significantly lower in those with refractory/early relapsed disease. led by Megan Melody MD, MS and #ReemKarmali doi.org/10.1182/blooda…

Designing a strong bridge to CAR-T cells with bispecifics ow.ly/TSpT50Xh8x8 #immunobiologyandimmunotherapy